Novel targets of antifibrotic and anti-inflammatory treatment in CKD

Medicine and Dentistry

• Chronic Kidney Disease 100%
• Combination Therapy 50%
• Introspection 50%
• Diseases 33%
• Serositis 33%
• Nephropathy 33%
• Mammalian Target of Rapamycin 33%
• Therapeutic Procedure 33%
• Patient 33%
• Prevalence 16%
• Pathogenesis 16%
• Epidemic 16%
• Obesity 16%
• Fibrosis 16%
• Population 16%
• Mitochondrial Biogenesis 16%
• Renal Replacement Therapy 16%
• Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase 16%
• Development 16%
• Sirtuin 16%
• Blood Vessel Calcification 16%
• Antifibrotic Agent 16%
• Comprehension 16%
• Clinician 16%
• Hope 16%
• Clotiazepam 16%
• Family 16%
• Kidney 16%
• Transforming Growth Factor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Kidney Failure 100%
• Diseases 33%
• Kidney Disease 33%
• Anti-Inflammatory Drug 33%
• Prevalence 16%
• Obesity 16%
• Pathogenesis 16%
• Diabetes Mellitus 16%
• Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase 16%
• Fibrosis 16%
• Epidemic 16%
• Blood Vessel Calcification 16%
• Clotiazepam 16%
• Sirtuin 16%
• Antifibrotic Agent 16%
• Transforming Growth Factor 16%

Biochemistry, Genetics and Molecular Biology

• Introspection 50%
• Mitochondrial Biogenesis 16%
• Development 16%
• Prevalence 16%
• NAD(P)H Oxidase 16%
• Population 16%
• Energy 16%
• Comprehension 16%
• Hope 16%
• Transforming Growth Factor 16%